A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs GSK-3511294 (Primary)
- Indications Asthma
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 11 Oct 2017 Planned initiation date changed from 3 Oct 2017 to 16 Oct 2017.
- 25 Sep 2017 New trial record
- 21 Sep 2017 Planned initiation date changed from 25 Sep 2017 to 3 Oct 2017.